Patient
SITE003-0106
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE003 (CAN) (Dr. Okafor)
consented 2026-01-12
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-24 (study day 162); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-11-21 (study day 129); relationship: NOT RELATED
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 114); relationship: not assessed
Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 108); relationship: RELATED
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 95); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 92); relationship: NOT RELATED
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-11 (study day 88); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-25 (study day 10); relationship: NOT RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.